ANTX
Price
$1.08
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
32.44M
40 days until earnings call
MNMD
Price
$6.55
Change
-$0.19 (-2.82%)
Updated
Jun 27 closing price
Capitalization
495.63M
47 days until earnings call
Interact to see
Advertisement

ANTX vs MNMD

Header iconANTX vs MNMD Comparison
Open Charts ANTX vs MNMDBanner chart's image
AN2 Therapeutics
Price$1.08
Change-$0.00 (-0.00%)
Volume$51.23K
Capitalization32.44M
Mind Medicine (MindMed)
Price$6.55
Change-$0.19 (-2.82%)
Volume$2.16M
Capitalization495.63M
ANTX vs MNMD Comparison Chart in %
Loading...
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANTX vs. MNMD commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a Buy and MNMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (ANTX: $1.08 vs. MNMD: $6.56)
Brand notoriety: ANTX and MNMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANTX: 19% vs. MNMD: 142%
Market capitalization -- ANTX: $32.44M vs. MNMD: $495.63M
ANTX [@Biotechnology] is valued at $32.44M. MNMD’s [@Biotechnology] market capitalization is $495.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANTX’s FA Score shows that 1 FA rating(s) are green whileMNMD’s FA Score has 1 green FA rating(s).

  • ANTX’s FA Score: 1 green, 4 red.
  • MNMD’s FA Score: 1 green, 4 red.
According to our system of comparison, MNMD is a better buy in the long-term than ANTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANTX’s TA Score shows that 3 TA indicator(s) are bullish while MNMD’s TA Score has 4 bullish TA indicator(s).

  • ANTX’s TA Score: 3 bullish, 5 bearish.
  • MNMD’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ANTX and MNMD are a bad buy in the short-term.

Price Growth

ANTX (@Biotechnology) experienced а -2.27% price change this week, while MNMD (@Biotechnology) price change was -6.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

ANTX is expected to report earnings on Aug 07, 2025.

MNMD is expected to report earnings on Aug 14, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNMD($496M) has a higher market cap than ANTX($32.4M). MNMD YTD gains are higher at: -5.747 vs. ANTX (-22.101). ANTX has higher annual earnings (EBITDA): -47.8M vs. MNMD (-75.18M). MNMD has more cash in the bank: 212M vs. ANTX (67.1M). ANTX (0) and MNMD (0) have equivalent revenues.
ANTXMNMDANTX / MNMD
Capitalization32.4M496M7%
EBITDA-47.8M-75.18M64%
Gain YTD-22.101-5.747385%
P/E RatioN/AN/A-
Revenue00-
Total Cash67.1M212M32%
Total DebtN/A22M-
FUNDAMENTALS RATINGS
ANTX vs MNMD: Fundamental Ratings
ANTX
MNMD
OUTLOOK RATING
1..100
1063
VALUATION
overvalued / fair valued / undervalued
1..100
11
Undervalued
30
Undervalued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
8759
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANTX's Valuation (11) in the Managed Health Care industry is in the same range as MNMD (30) in the null industry. This means that ANTX’s stock grew similarly to MNMD’s over the last 12 months.

MNMD's Profit vs Risk Rating (97) in the null industry is in the same range as ANTX (100) in the Managed Health Care industry. This means that MNMD’s stock grew similarly to ANTX’s over the last 12 months.

MNMD's SMR Rating (96) in the null industry is in the same range as ANTX (96) in the Managed Health Care industry. This means that MNMD’s stock grew similarly to ANTX’s over the last 12 months.

MNMD's Price Growth Rating (59) in the null industry is in the same range as ANTX (87) in the Managed Health Care industry. This means that MNMD’s stock grew similarly to ANTX’s over the last 12 months.

MNMD's P/E Growth Rating (100) in the null industry is in the same range as ANTX (100) in the Managed Health Care industry. This means that MNMD’s stock grew similarly to ANTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANTXMNMD
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 23 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NILIX15.40N/A
N/A
Neuberger Berman International Sel I
MEMAX38.21N/A
N/A
MFS Emerging Markets Equity A
LAVRX15.25N/A
N/A
Lord Abbett Fundamental Equity R3
EISDX26.71N/A
N/A
Carillon ClariVest Intl Stock C
GSAEX24.62N/A
N/A
Goldman Sachs China Equity Inv

ANTX and

Correlation & Price change

A.I.dvisor tells us that ANTX and NKTX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ANTX and NKTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
-0.46%
NKTX - ANTX
26%
Poorly correlated
-3.18%
CSLLY - ANTX
26%
Poorly correlated
-2.96%
RANI - ANTX
25%
Poorly correlated
+6.50%
CERO - ANTX
24%
Poorly correlated
-14.34%
MNMD - ANTX
23%
Poorly correlated
-2.67%
More

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with ATAI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
-2.67%
ATAI - MNMD
54%
Loosely correlated
-2.67%
BEAM - MNMD
50%
Loosely correlated
-2.04%
EYPT - MNMD
50%
Loosely correlated
-6.94%
CRSP - MNMD
49%
Loosely correlated
+1.69%
RXRX - MNMD
49%
Loosely correlated
-6.94%
More